

New protocols	Protocols recently updated	Document updates
<p>ID 3464 Ewing sarcoma VDC/IE (vincristine doxorubicin cyclophosphamide/ifosfamide etoposide) overview</p> <p>ID 1916 Ewing sarcoma VDC (vincristine doxorubicin cyclophosphamide) (part 1 of VDC/IE)</p> <p>ID 3465 Ewing sarcoma IE (ifosfamide etoposide) (part 2 of VDC/IE)</p> <p>ID 3470 Ewing sarcoma VIDE followed by VAC or VAI overview</p> <p>ID 3471 Ewing sarcoma VIDE (vincristine ifosfamide doxorubicin etoposide) (part 1 of VIDE followed by VAC or VAI)</p> <p>ID 3472 Ewing sarcoma VAC (vincristine dactinomycin cyclophosphamide) (part 2a of VIDE followed by VAC or VAI)</p> <p>ID 3473 Ewing sarcoma VAI (vincristine dactinomycin ifosfamide) (part 2a of VIDE followed by VAC or VAI)</p> <p>ID 1378 Gestational trophoblastic disease high risk EP-EMA (etoposide cisplatin etoposide methotrexate dactinomycin)</p>	<p>ID 153 Breast adjuvant PACLitaxel weekly and trastuzumab three weekly Evidence update to include use as a standalone regimen in low risk disease.</p> <p>ID 552 Prostate metastatic zoledronic acid Change to dose frequency and evidence update.</p> <p>ID 149 Breast metastatic zoledronic acid Evidence update regarding frequency of administration.</p>	<p>ID 123 Immediate management of neutropenic fever Minor changes to definition of neutropenic fever. Changes to dosing</p>